Micro Hospitals
Market Cap
₹1,175 ₹1,175 Cr.
P/E
45.50
PEG
1.39
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis is live if new Indian beds—especially Navi Mumbai and Nashik—reach commercial utilization while Uganda remains resilient and the Mwanza/Dar es Salaam capacity plan progresses.

The bull path requires faster Indian and Tanzanian ramp-up plus stronger Uganda ARPOB and occupancy; the bear path is driven by break-even failure, licensing or takeover delays, and weaker Uganda collections or utilization.

Margin is initially pressured by expansion costs, so sustained profitability depends on mature Uganda operations and later fixed-cost absorption offsetting startup drag.

Key Ratios

Debt to Equity
Debt to Equity
0.16
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
14.01 %
Institutions
Institutions
0.48 %
Market cap
Market cap
1,175 Cr
No. of Shareholders
No. of Shareholders
1,162
OPM (%)
OPM (%)
-
PE
PE
45.50
Prom Holding
Prom Holding
69.53 %
ROCE (%)
ROCE (%)
21.62
ROE (%)
ROE (%)
18.77
Sales
Sales
131 Cr
  • Unihealth Hospitals
  • GPT Healthcare
  • Guj. Kidney & Super
Last updated on 3 Sep 2026
  • Unihealth Hospitals runs owned hospitals in Uganda, Nigeria and India including 50-bed Navi Mumbai, plus pharma distribution and consultancy.
  • Uganda is the earnings base; India beds are the growth vector; forex swings drive volatility.
  • Adding Nashik 200-bed and Tanzania beds toward 1,000-bed asset-light network; per management no near-term dilution.
  • In expansion build; near term rides on Nashik ramp and 99.8%-owned Uganda earnings; FY27 revenue guided ₹250–300Cr, EBITDA margin early-mid 30s.
  • Profit stays concentrated in Uganda at ~85%; per management single-geography target still unmet.
  • Nashik 200-bed commissioning H1 FY27
    200 beds come online; initial occupancy feeds ₹250–300Cr FY27 revenue guide.
  • Dar es Salaam 100-bed acquisition FY27
    adds 100-bed Tanzania hospital; deal still in discussions.
  • Mwanza 20-bed upgrade Q3 FY27
    dialysis unit becomes secondary care; approval pending after 2+ year delay.
  • Victoria Hospital swap details Next quarter / annual report
    disclosure sets shares issued, effective date and attributable profit.
  • Income-tax appeals No timeline
    outcome decides ₹399L plus ₹326L cash outflow risk.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
134
52W Range
High
820
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Unihealth Hospitals Ltd. Business

Unihealth Consultancy Limited is a healthcare service provider operating in Mumbai, India and various African countries. Their services include medical centers, hospitals, consultancy, pharmaceutical product distribution, and medical value travel.

Unihealth Hospitals major competitors are GPT Healthcare, Guj. Kidney & Super, Shalby, Gaudium IVF & Women, Suraksha Diagnostic, Rays Of Belief, Asarfi Hospital Ltd..
Market Cap of Unihealth Hospitals is ₹1,175 Crs.
While the median market cap of its peers are ₹1,306 Crs.

Unihealth Hospitals seems to be less financially stable compared to its competitors.
Altman Z score of Unihealth Hospitals is 8.3 and is ranked 4 out of its 8 competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation May Nov Dec
Conference Call Mar Dec
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material